Encyclopedia of contested claims
Current medical guidance does not support using ivermectin in place of established cancer treatments such as surgery, radiation therapy, chemotherapy, immunotherapy, hormone therapy, or targeted therapy. People considering ivermectin should discuss it with their oncology team because delaying standard care can affect outcomes and ivermectin can cause side effects or drug interactions.
9 reviewing models concluded the claim is not supported by the available evidence.
The Adjudged panel has not yet completed its independent review of this claim. This first-pass draft summarizes the main issues the panel is likely to examine, including the difference between laboratory findings and clinical benefit, the safety considerations of ivermectin use in people with cancer, and the risks of substituting an unestablished approach for oncology treatments with clinical evidence.
Current medical guidance does not support using ivermectin in place of established cancer treatments such as surgery, radiation therapy, chemotherapy, immunotherapy, hormone therapy, or targeted therapy. People considering ivermectin should discuss it with their oncology team because delaying standard care can affect outcomes and ivermectin can cause side effects or drug interactions.
The claim asks whether ivermectin, a drug mainly used to treat certain parasitic infections, is a safe alternative to standard cancer treatment. In this context, “alternative” means using ivermectin instead of treatments recommended by oncology clinicians, rather than as part of a monitored clinical trial or as a treatment for a parasitic infection.
Interest in ivermectin and cancer often comes from laboratory studies in cells or animals, online anecdotes, or discussions of possible biological mechanisms. Those forms of evidence can be useful for generating research questions, but they do not by themselves establish that a drug helps people with cancer live longer, shrink tumors, improve symptoms, or avoid harm.
Standard cancer treatments vary by cancer type, stage, tumor biology, overall health, and patient goals. They are generally recommended after clinical studies assess benefits, risks, dosing, and which patients are most likely to benefit.
The strongest basis for using a cancer treatment is usually evidence from well-designed clinical trials in people, especially trials that measure outcomes such as survival, disease progression, tumor response, quality of life, and treatment-related harms. At present, major cancer information organizations do not recommend ivermectin as a substitute for standard cancer care.
Some preclinical studies have reported that ivermectin can affect cancer-related pathways in cells or animal models. However, effects seen in a lab dish may require concentrations or conditions that are not achievable or safe in humans, and many promising laboratory findings do not become effective cancer treatments.
Ivermectin has approved medical uses at appropriate doses, but “has approved uses” is not the same as “safe for cancer treatment.” Higher or unsupervised doses may cause adverse effects, including nausea, dizziness, low blood pressure, confusion, seizures, or other neurologic symptoms, and risks may be different in people receiving chemotherapy, targeted therapy, immunotherapy, anti-nausea drugs, blood thinners, or other medicines.
A major safety issue is the opportunity cost of replacing established treatment. If a person delays or stops recommended cancer care in favor of ivermectin, the cancer may progress during a period when evidence-based treatment could have been more effective.
Research uncertainty remains about whether ivermectin or related compounds could have a future role in oncology under specific conditions, such as in combination with other treatments, for particular tumor types, or at carefully studied doses. That possibility would need to be tested through properly designed clinical trials before it could guide routine care.
There may also be uncertainty for individual patients who have limited treatment options or who are considering participation in a trial. Those decisions require a clinician who can review the cancer type, stage, prior treatments, organ function, current medications, and trial eligibility.
Uncertainty about future research does not make ivermectin a safe replacement for standard cancer treatment today. The practical question for patients is whether to substitute it for established care, and current clinical guidance weighs against doing so outside an appropriate research setting.
The umbrella claim is actually several claims bundled into one. Each needs its own evaluation.
| Model | Part 1 | Part 2 | Part 3 | Overall |
|---|---|---|---|---|
| Grok 4.3 | No · 88% | No · 90% | No · 72% | No · 90% |
| Mistral Medium 3.5 | No · 88% | No · 90% | No · 72% | No · 90% |
| OpenAI GPT-5.4 | No · 88% | No · 90% | No · 72% | No · 90% |
| Llama 4 Maverick | No · 88% | No · 90% | No · 72% | No · 90% |
| Claude Opus 4.7 | No · 88% | No · 90% | No · 72% | No · 90% |
| Gemini 3.1 Pro | No · 88% | No · 90% | No · 72% | No · 90% |
| DeepSeek V4 Pro | No · 88% | No · 90% | No · 72% | No · 90% |
| Qwen 3.7 Max | No · 88% | No · 90% | No · 72% | No · 90% |
| GLM 5.1 | No · 88% | No · 90% | No · 72% | No · 90% |
| Kimi K2.6 | — | — | — | Incomplete |
The current evidence leans one way. But we're not committed to the conclusion, we're committed to the evidence.
No, ivermectin is not supported as a safe or effective alternative to standard cancer treatments such as surgery, chemotherapy, radiation, or immunotherapy. Authoritative sources including the American Cancer S...
The claim that ivermectin is a safe alternative to standard cancer treatment is not supported by current medical evidence. Ivermectin has not been proven in rigorous human cancer trials to be as effective as es...
No. Based on current medical evidence and guidance, ivermectin is not a safe alternative to standard cancer treatment, and it has not been shown in rigorous human trials to work as well as established therapies...
No, ivermectin is not a safe alternative to standard cancer treatment. Confidence: High. The claim is contradicted by multiple reputable sources, including the American Cancer Society and Macmillan Cancer Suppo...
No. Ivermectin is not an established or safe alternative to standard cancer treatment. There is no rigorous human clinical trial evidence showing that ivermectin treats cancer as effectively as surgery, radiati...
No, ivermectin is not a safe alternative to standard cancer treatment. Confidence: High Key Evidence: Current medical guidance from leading health organizations, including the American Cancer Society, Macmillan...
Current medical evidence does not support the claim that ivermectin is a safe alternative to standard cancer treatment. Using ivermectin in place of surgery, radiation, chemotherapy, immunotherapy, hormone ther...
No, ivermectin is not a safe or effective alternative to standard cancer treatment. Current medical guidance from major oncology organizations, such as the American Cancer Society and the National Comprehensive...
No, ivermectin is not a safe alternative to standard cancer treatment. Confidence is high. Current medical guidance from major health organizations explicitly states that ivermectin should not be used in place...
